Roche and reMYND enter into a strategic alliance to develop treatments for Parkinson’s and Alzheimer’s disease

10-Sep-2010 - Switzerland

Roche and reMYND announced that they have entered into an agreement to develop novel therapeutics that could slow down neurodegeneration in Parkinson’s and Alzheimer’s patients by inhibiting alpha-synuclein and tau toxicity.

The collaboration will focus on two of reMYND’s pre-clinical small molecule programmes targeting alpha-synuclein and tau related pathologies in appropriate model systems as well as potential back-up classes. Roche and reMYND will form joint teams to progress the programmes towards clinical studies. Roche will provide input into chemistry, lead-optimisation and pre-clinical development, while reMYND will continue to conduct non-clinical pharmacology studies and further elucidate the underlying molecular mechanisms. Roche will be responsible for all clinical development and worldwide commercialisation.

Under the agreement, reMYND could receive over half a billion Euros in milestone payments, additional FTE payments and royalties on resulting net sales, potentially reaching a double-digit level.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances